At the BIO2026 industry event in June 2026, NVIDIA positioned AI as a "lab partner" for life sciences and drug discovery. Anchored by a panel discussion with major pharma firms including Genentech, the company emphasized supplying AI infrastructure to automate and accelerate drug discovery and laboratory operations.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.